Antitumor activity of the c-Myc inhibitor KSI-3716 in gemcitabine-resistant bladder cancer. - Wikidata - wikimedia - TriplyDB

Antitumor activity of the c-Myc inhibitor KSI-3716 in gemcitabine-resistant bladder cancer.

Antitumor activity of the c-Myc inhibitor KSI-3716 in gemcitabine-resistant bladder cancer.

http://www.wikidata.org/entity/Q37660290

about

MicroRNA-33b suppresses migration and invasion by targeting c-Myc in osteosarcoma cells Strategies to Inhibit Myc and Their Clinical Applicability Tetracycline-inducible shRNA targeting long non-coding RNA PVT1 inhibits cell growth and induces apoptosis in bladder cancer cells JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer.ASP5878, a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance.Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640.The association between rs9642880 gene polymorphism and bladder cancer risk: a meta-analysis.hsa‑miR‑24 suppresses metastasis in nasopharyngeal carcinoma by regulating the c‑Myc/epithelial‑mesenchymal transition axis

P2860

Q35535148-D8FE43B4-7E2B-4467-8BCD-B33993800878 Q36303678-C10C85D6-4A2F-46F8-B265-87CC4870EC6F Q36562321-627480E7-468C-4916-8A73-9029319B8FF4 Q37687075-6EC4CC37-8A15-4CB0-B9EE-99CAE1F332B6 Q38729065-3FBD8036-83FD-4244-8431-8DF79D3F3B0B Q39496138-5D364201-E7DA-4E91-9F3E-633CBE6602DF Q41912821-CD9B4D0C-1A69-42DF-A4A3-83A733FA800C Q58758617-897DB838-87BA-4981-B9CE-4B3C17D45140

P2860

Antitumor activity of the c-Myc inhibitor KSI-3716 in gemcitabine-resistant bladder cancer.

http://www.wikidata.org/entity/Q37660290

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Antitumor activity of the c-My ...... bine-resistant bladder cancer.

@en

Antitumor activity of the c-My ...... bine-resistant bladder cancer.

@nl

type

label

Antitumor activity of the c-My ...... bine-resistant bladder cancer.

@en

Antitumor activity of the c-My ...... bine-resistant bladder cancer.

@nl

prefLabel

Antitumor activity of the c-My ...... bine-resistant bladder cancer.

@en

Antitumor activity of the c-My ...... bine-resistant bladder cancer.

@nl

P1433

Q37660290-CCAF217A-FB6B-42C5-9537-A4EEABE9CB26

P1476

Q37660290-22FCDFC7-539B-4B3C-A1EA-2173CBACABB7

P2093

Q37660290-079EC415-ED09-4A00-9E25-C824571796FF

Q37660290-0E902BEF-4995-4A0E-A656-3DD43715DADD

Q37660290-2722108C-5835-4810-81C3-BC49E3C1427A

Q37660290-2B683222-B2AE-4901-8A93-08CB4E9D2F86

Q37660290-35C2613E-5497-4AD8-AFA5-635A4A44418C

Q37660290-8467E34C-E9F3-4707-8F4A-6ED2C02339C7

Q37660290-B853684A-6870-45AB-854F-E951D9DC80B1

P2860

Q37660290-0F3BD1D3-E37E-4BA7-A640-394B787432B2

Q37660290-206A86B8-0CC8-44D9-A791-76B0231E087E

Q37660290-329C85C6-F137-4B41-ADF7-7833073F9A7F

Q37660290-3C0BB191-18B8-4D3A-82F1-E442D5AF1DB8

Q37660290-44CA8BDD-D4CF-4979-8D30-D037F8AA9615

Q37660290-4DE7DF03-D9AC-4FAF-B7E8-3F84ABB613EE

Q37660290-51165247-BC63-40D7-8530-8420C6E28A97

Q37660290-5843DBC4-0F13-4093-83B2-3CF53DBC6C9F

Q37660290-77AA3DC4-A1C5-47D6-8A8F-5E6D96FCBCC2

Q37660290-8030DF05-723D-4867-9194-17905A65AB7B

P304

Q37660290-D9113255-8651-4A5C-B510-25E0C3196A17

P31

Q37660290-F5A27657-818C-4795-80EB-CD838CC1074E

P356

Q37660290-185BFA69-6C08-41A4-82B4-A54AFED9B2D5

P407

Q37660290-70A3E935-444D-4A8E-AEA2-CA770F8638EC

P433

Q37660290-FADCADF8-84E5-4CFA-87B8-C5D5C579528F

P478

Q37660290-AFCF5573-8B2F-4781-B64A-DE1876271548

P50

Q37660290-5031BD20-97CE-4713-9977-2F9D429291FF

P577

Q37660290-549CAF05-0A8D-4CBE-B76E-73D83E2C090F

P698

Q37660290-C90E67C8-8489-43E6-A26B-92ECCC2F8D65

P932

Q37660290-8505D84C-FE72-4B55-955C-8299D3693518

P356

ONCOTARGET.1545

P1433

P1476

Antitumor activity of the c-My ...... abine-resistant bladder cancer

@en

P2093

Ji-Sun Shin

http://www.w3.org/2001/XMLSchema#string

Kang Hyun Lee

http://www.w3.org/2001/XMLSchema#string

Kyung-Chae Jeong

http://www.w3.org/2001/XMLSchema#string

Kyung-Ohk Ahn

http://www.w3.org/2001/XMLSchema#string

Nae-Rae Jung

http://www.w3.org/2001/XMLSchema#string

Sang-Jin Lee

http://www.w3.org/2001/XMLSchema#string

Weon Seo Park

http://www.w3.org/2001/XMLSchema#string

P2860

Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer

Cancer statistics, 2013

Stem cells, cancer, and cancer stem cells

Mechanisms of cancer drug resistance

MYC on the path to cancer

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer.

Cellular pharmacology of gemcitabine.

Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology.

Systemic chemotherapy for patients with bladder cancer--current controversies and future directions.

P304

326-337

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.1545

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24504118

http://www.w3.org/2001/XMLSchema#string

P932

3964210

http://www.w3.org/2001/XMLSchema#string